About BioArray Solutions
BioArray Solutions is a company based in New York (United States) founded in 2001 was acquired by Immucor in March 2008. BioArray Solutions has raised $11.83 million across 2 funding rounds from investors including Immucor. BioArray Solutions operates in a competitive market with competitors including Inflammatix, StrideBio, Agendia, LogicBio and Phase Genomics, among others.
- Headquarter New York, United States
- SectorsHealthcare
- Website bioarrays.com
- Social LinkedIn
- Acquired by Immucor (Mar 2008)
Funding Insights of BioArray Solutions
BioArray Solutions has successfully raised a total of $11.83M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $1.31 million completed in June 2005. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $11.83M
- Total Rounds 2
- Last Round Series B — $1.31M
- First Round $10.52M
(Jan 2005)
All 2 funding rounds of BioArray Solutions with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2005 | $1.31M | Series B | – | – | – |
| Jan 2005 | $10.52M | Series B | – | – | – |
1 investors in total: 1 institutional.
Investors in BioArray Solutions
BioArray Solutions has secured backing from 1 investor. Prominent investors backing the company include Immucor.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Transfusion and transplantation diagnostic products are provided by Immucor. | 1982 | immucor.com | United States |
Investor details for BioArray Solutions
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of BioArray Solutions
4 dated milestones of BioArray Solutions across 7 years, from founding to its latest funding, stage changes and deals.
- Founded BioArray Solutions is founded.
- Funding First funding round of $10.5M.
- Funding Latest funding round, Series B, of $1.3M.
- Exit Acquired by Immucor.
Competitors of BioArray Solutions
BioArray Solutions operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Inflammatix, StrideBio, Agendia, LogicBio and Phase Genomics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| inflammatix.com | 2016 | San Francisco, United States | $191.47M | 54 | Provider of diagnostic solutions for systemic infections | |
| stridebio.com | 2015 | Durham, United States | $98.2M | 109 | AAV-based gene therapies for rare diseases are developed. | |
| agendia.com | 2003 | Irvine, United States | $123M | 203 | Genomic diagnostic products for cancer treatment are provided. | |
| logicbio.com | 2013 | Lexington, United States | $49M | 62 | Viral vectors are developed for genetic and infectious disease treatments. | |
| phasegenomics.com | 2015 | Seattle, United States | $5.75M | 19 | Laboratory and computational services for DNA proximity analysis are provided. | |
| candeltx.com | 1999 | United States | $110.3M | 76 | Viral immunotherapies are developed for cancer treatment. | |
| sixfold.bio | 2017 | London, United Kingdom | $4.59M | 16 | Oligonucleotide delivery systems are developed for targeted gene therapy. | |
| genedit.com | 2016 | Berkeley, United States | $93.5M | 34 | Genetic medicines are delivered using polymer nanoparticle platforms. | |
| vigenebio.com | 2012 | Rockville, United States | $10.5M | 45 | Research reagents for drug discovery and functional genomics are developed. | |
| mekonos.com | 2016 | Palo Alto, United States | $29.6M | – | Silicon-based nanomachine chips are developed for cell engineering applications. |
Detailed competitors of BioArray Solutions
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Similar companies to BioArray Solutions
10 companies that operate in the same segment as BioArray Solutions (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about BioArray Solutions
BioArray Solutions was founded in 2001 and raised its 1st funding round 4 years after it was founded.
BioArray Solutions is headquartered in New York, United States. It is registered at New York, New York, United States.
BioArray Solutions is a funded company, having raised a total of $11.83M across 2 funding rounds to date. The company's 1st funding round was a Series B of $10.52M, raised on Jan 2005.
BioArray Solutions was founded in 2001 in New York, United States, within the biotechnology sector. Bead-based assays for nucleic acid and protein analysis are developed, along with products for genetic diagnostics and infectious disease profiling. The BeadChip system, featuring encoded microparticles for molecular analysis, has received FDA clearance for an autoantibody profiling assay. The company was acquired by Immucor in March 2008.
BioArray Solutions's top competitors include Inflammatix, Phase Genomics and Genedit.
BioArray Solutions has 1 investor. Key investors include Immucor.
Yes. BioArray Solutions was acquired by Immucor in March 2008.